Cormet Hip Resurfacing System
Corin U
FDA Clearance Information
The Cormet Hip Resurfacing System received FDA premarket approval (PMA) on July 17, 2020. It is manufactured by Corin U and classified as a Class 3 device under product code NXT.
What It Is
FDA-Cleared Indications
- FDA-approved labeling was updated to include a summary of results from the completed long-term post-approval study.
- The device is indicated for hip resurfacing arthroplasty in appropriately selected patients according to the approved labeling.
Clinical Applications
- Hip resurfacing arthroplasty as an alternative to total hip arthroplasty in selected patients.
- Treatment of end-stage hip joint disease requiring arthroplasty.
- Treatment planning for appropriately selected younger or active patients when femoral bone preservation is clinically important.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- This is a metal-on-metal implant; patients require appropriate clinical follow-up for implant performance and possible metal-related complications.
- The implant is selected in multiple sizes to match patient anatomy; sizing and component positioning are determined during preoperative planning and surgery.
- It is implanted surgically through the hip and requires preparation of the femoral head and acetabulum.
- Patient selection is important. Femoral head or neck bone quality, anatomy, kidney function, allergy history, and conditions that increase fracture or implant-failure risk should be reviewed.
- MRI safety and scanning conditions depend on the current implant labeling and the complete implanted construct. Patients should provide the implant identification information to the MRI facility before scanning.
Frequently Asked Questions
What are the clinical indications for Cormet Hip Resurfacing System?
The device is indicated for use in younger, active patients requiring hip arthroplasty, with a focus on bone preservation and reduced dislocation risk.
What outcomes have been reported in clinical studies?
Studies report a 93% survivorship at 11 years, with benefits including bone preservation and high performance in active patients.
What complications have been reported?
Safety data indicate potential heat generation during preparation, which could lead to osteonecrosis if not managed properly.